These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030 [TBL] [Abstract][Full Text] [Related]
6. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010 [TBL] [Abstract][Full Text] [Related]
7. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Del Rio-Moreno M; Alors-Perez E; Borges de Souza P; Prados-Gonzalez ME; CastaÑo JP; Luque RM; Gahete MD Transl Res; 2019 Sep; 211():147-160. PubMed ID: 30904441 [TBL] [Abstract][Full Text] [Related]
9. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin. Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790 [TBL] [Abstract][Full Text] [Related]
12. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783 [TBL] [Abstract][Full Text] [Related]
13. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304 [TBL] [Abstract][Full Text] [Related]
14. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma. Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer. Zhang X; Wang Y; Ning Y Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181 [TBL] [Abstract][Full Text] [Related]
16. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer. Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945 [TBL] [Abstract][Full Text] [Related]
17. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells. Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954 [TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364 [TBL] [Abstract][Full Text] [Related]
19. MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Wang L; Song G; Tan W; Qi M; Zhang L; Chan J; Yu J; Han J; Han B Oncotarget; 2015 Nov; 6(34):35978-90. PubMed ID: 26451614 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt/β-catenin signaling. Guan H; Liu C; Fang F; Huang Y; Tao T; Ling Z; You Z; Han X; Chen S; Xu B; Chen M Oncotarget; 2017 Feb; 8(9):14693-14707. PubMed ID: 28107193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]